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Abstract
Background: Endothelial dysfunction plays a central role in atherosclerotic progression and
cardiovascular complications of type 2 diabetes mellitus (T2DM). Given the role of nitric oxide in
the vascular system, we aimed to test hypotheses of synergy between the common endothelial
nitric oxide synthase (eNOS) Asp298 allele and T2DM in predisposing to acute myocardial infarction
(AMI).
Methods: In a population-based patient survey with 403 persons with T2DM and 799 healthy
subjects from the population without diabetes or hypertension, we analysed the relation between
T2DM, sex and the eNOS Asp298 allele versus the risk for AMI.
Results: In an overall analysis, T2DM was a significant independent risk factor for AMI. In patients
with T2DM, homozygosity for the eNOS Asp298 allele was a significant risk factor (HR 3.12 [1.49–
6.56], p = 0.003), but not in subjects without diabetes or hypertension.
Compared to wild-type non-diabetic subjects, all patients with T2DM had a significantly increased
risk of AMI regardless of genotype. This risk was however markedly higher in patients with T2DM
homozygous for the Asp298 allele (HR 7.20 [3.01–17.20], p < 0.001), independent of sex, BMI,
systolic blood pressure, serum triglycerides, HDL -cholesterol, current smoking, and leisure time
physical activity. The pattern seemed stronger in women than in men.
Conclusion: We show here a strong independent association between eNOS genotype and AMI
in patients with T2DM. This suggests a synergistic effect of the eNOS Asp298 allele and diabetes,
and confirms the role of eNOS as an important pathological bottleneck for cardiovascular disease
in patients with T2DM.
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Background
Diabetes constitutes one of the major independent cardi-
ovascular risk factors, and patients with this disease suffer
from premature cardiovascular morbidity and mortality.
Endothelial dysfunction is regarded as an early step in the
development of insulin resistance and T2DM as well as
important for the atherosclerotic predisposition and car-
diovascular complications associated with diabetes [1].
Endothelial Nitric Oxide (NO) is a critical actor in the
pathophysiology of the vascular system [1-3] and is
involved in preventing the oxidation of lipoproteins, in
down-regulating inflammatory mediators, preventing the
adhesion of monocytes to the endothelium, controlling
the expression of proteins involved in atherogenesis, and
in inhibiting the proliferation of vascular smooth muscle
cells [1,2]. Furthermore, it has a protective effect in angina
and the acute coronary syndrome by promoting vessel
vasodilation and by inhibiting platelet adhesion and
aggregation [1,2,4]. A reduced bioavailability of NO may
result from down-regulated protein expression, depressed
activation, or reduced enzymatic function of endothelial
nitric oxide synthase (eNOS) or from increased consump-
tion and inactivation of the NO produced [2,5,6]. Ele-
vated glucose, smoking, inflammation and oxidative
stress result in the production of reactive oxygen species
(ROS) that directly can scavenge NO [2,7]. Several risk fac-
tors for coronary artery disesase (CAD) such as smoking,
elevated homocysteine, free fatty acids, hypertension,
insulin resistance, and diabetes also depress eNOS [2,6,8].
The Glu298Asp polymorphism is the only coding region
variant identified in the eNOS gene and has been associ-
ated with an increased risk of ischemic heart disease
(IHD) [9,10]. Findings suggest that subjects carrying the
Asp298 allele generate lower NO in vivo and could be more
susceptible to endothelial dysfunction [11], however the
genotype effect may be restricted to endothelial cells as
results indicate that there is no direct effect of the poly-
morphism on NO production in platelets [12]. Other fac-
tors which reduce NO bioavailability could hypothetically
act in synergy with the Asp298 allele and precipitate condi-
tions of inadequate NO bioavailability. This could result
in endothelial vulnerability and a more prothrombotic
state in the case of endothelial damage or plaque rupture.
In this study, we aimed to test this hypothesis by focusing
on a possible synergistic effect of T2DM and the eNOS
Asp298 allele with respect to AMI morbidity.
Methods
Subjects
In Skara, a small community in the Skaraborg County in
southwestern Sweden, patients with hypertension and/or
diabetes have been treated at special outpatient clinics
within primary care since the 1970s (The Skaraborg
Hypertension Project) [13]. From 1992 to 1993, all 1149
patients with hypertension and/or T2DM who completed
an annual check-up at the hypertension and diabetes
clinic in Skara were consecutively surveyed for cardiovas-
cular risk factors (The Skaraborg Hypertension and Diabe-
tes Project) [14,15]. From 1993 to 1994, a population
survey using the same protocol as the patient survey was
conducted with a randomized sample from the popula-
tion census register, stratified by age and sex [16]. Out of
1400 invited subjects = 40 years of age, 1109 (80%) com-
pleted the study visit. Among the patients, 454 subjects
were diagnosed with diabetes. After the exclusion of
patients with type 1 diabetes (n = 33), missing blood sam-
ples (n = 12), and unsuccessful genotyping (n = 6), 403
patients remained for further analyses in the current
study. In the population survey of 1109 persons, we iden-
tified 824 participating subjects who neither had hyper-
tension nor diabetes [17] that was used as a reference
group. Previous cardiovascular event was not an exclusion
criteria. Out of these, 799 subjects were successfully geno-
typed. The characteristics of the study population are
shown in table 1.
The regional ethical review board at Gothenburg Univer-
sity, Gothenburg, Sweden, approved both surveys. Sub-
jects received both written and oral information and were
included after giving consent. The study was carried out in
accordance with the principles of the Declaration of Hel-
sinki.
Methods
Procedures in this project have been published in detail
previously [14-18]. Participants were seen in the morning
after an overnight fast (10 h) and venous blood samples
were drawn. Body weight and height were measured in
light clothes and no shoes. Blood pressure was measured
in a supine position after 5 minutes rest (arm in heart level
and cuff size adjusted for arm circumferences) [14]. Infor-
mation on medical history and ongoing medication was
collected and participants answered a validated question-
naire on smoking habits, alcohol consumption, and phys-
ical activity [14]. Current smoking was defined as daily
smoking (yes/no). Leisure time physical activity (LTPA)
was divided into those who exercised (walking and gar-
dening included) for at least 4 hours per week in their lei-
sure time, and those who did not [17]. BMI was calculated
by weight (kg) × length-2 (m). Serum triglycerides and
HDL-cholesterol were analyzed using standard commer-
cial kits.
In accordance with national and international guidelines
at the time, diagnosis of hypertension was based on three
consecutive readings of diastolic blood pressure ≥ 90 mm
Hg, or ongoing treatment with blood pressure lowering
medications for hypertension [19]. Diagnosis of diabetes
was based on two fasting blood glucose values ≥ 6.7 mmolBMC Cardiovascular Disorders 2008, 8:36 http://www.biomedcentral.com/1471-2261/8/36
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L1, a 2 hour blood glucose value of ≥ 11.1 mmol L-1 in an
oral glucose tolerance test (OGTT), or a known diagnosis
of diabetes [20]. Differentiation between type 1 and
T2DM was based on clinical criteria.
The end-point register in the project includes fatal or non-
fatal first events of AMI and acute stroke (morbidity), all
fatal AMI and acute stroke events (mortality), and all-
cause mortality. Information on end-points, from base-
line through 2002, was ascertained by record linkage with
the Swedish national mortality and in-patient registers.
According to our previous evaluation this method is valid
[21]. With few exceptions, AMI events in the National reg-
istries could be confirmed in hospital records (19), and
more confirmed AMI cases were identified in National
registries as compared to local registries [22].
Experimental procedures
DNA preparation was performed as previously described
[23], diluted to 10 ng/ul and arrayed in microtiterplates.
PCR, sample preparation and genotyping of the eNOS
gene was performed as previously described in detail [24].
Briefly, a fragment overlapping the eNOS polymorphism
was amplified by PCR using the primers 5'-CGGCTGGAC-
CCCAGGAAACGG-3' and 5'-TCCAGGGGCACCTCAAG-
GACC-3'. Template preparation and annealing of
sequencing primer (5'-CAGAAGGAAGAGTTCTGGG-3')
was performed in a Magnatrix 1200 instrument (Magnetic
Biosolution, Stockholm, Sweden) with the standard
method and kit provided by the manufacturer, followed
by Pyrosequencing analysis on a PSQ™ HS 96 instrument
(Pyrosequencing, Uppsala, Sweden).
Statistical analysis
To test our primary hypothesis of a synergistic effect
between T2DM and endothelial dysfunction due to the
eNOS Asp298 allele, we categorised the study population
into subjects without diabetes and hypertension; Glu298/
Glu298 (1), Asp298/Glu298 (2), and Asp298/Asp298 (3), and
into subjects with T2DM; Glu298/Glu298 (4), Asp298/Glu298
(5), and Asp298/Asp298 (6), respectively, thereby generat-
ing six categories. The hazard ratios (HR) of AMI morbid-
ity were analysed pair-wise using category 1 as reference.
SPSS Base System for Macintosh 11.0 was used for data
analyses and all analyses were sex-specific. Means were
adjusted for age and proportions for characteristics of the
study population were age-standardised in ten-year inter-
vals using the whole Skara population ≥ 40 years as stand-
ard (Table 1). After controlling for that the assumption of
proportionality was met, HR were examined by Cox pro-
portional hazard model and expressed with 95 per cent
confidence interval. Confounders were accounted for in
multiple Cox regression models, by first entering age as
covariate, then age, BMI, HDL cholesterol, serum triglyc-
erides, daily smoking (yes/no), and leisure time physical
activity. In these models all covariates were entered as
continuous variables except for smoking which was
dichotomised as described above. Log transformation was
used to induce normality in serum triglycerides. Two-way
interaction terms were used to explore the interaction
Table 1: Descriptive characteristics of the study population
T2DM Controls
Men Women Men Women
(n = 202) (n = 201) (n = 391) (n = 408)
Variables (Units) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Age (years) 69.4 (9.3) 70.7 (10.2) 60.8 (13.1) 59.5 (12.4)
Waist hip ratio (WHR) (cm) 0.96 (0.06) 0.88 (0.07) 0.93 (0.08) 0.81 (0.08)
Body Mass Index (BMI) (kg m-2) 27.9 (3.7) 28.9 (4.9) 26.0 (3.6) 26.0 (4.7)
Systolic blood pressure (mm Hg) 154 (18.5) 154 (18.6) 133 (18.2) 136 (18.1)
Diastolic blood pressure (mm Hg) 86 (9.7) 83 (10.4) 76 (9.5) 74 (10.1)
Triglycerides (mmol/L) 1.6 (0.9) 1.6 (0.8) 1.2 (0.8) 1.1 (0.8)
Total Cholesterol (mmol/L) 5.7 (1.1) 6.0 (1.2) 5.9 (1.1) 6.1 (1.2)
LDL Cholesterol (mmol/L) 3.9 (1.0) 4.1 (1.1) 4.3 (1.0) 4.3 (1.1)
HDL Cholesterol (mmol/L) 1.0 (0.23) 1.1 (0.25) 1.1 (0.24) 1.2 (0.24)
n( % )n( % )n( % )n( % )
Smoking (yes or no) 41 (25.0) 27 (28.2) 83 (22.2) 76 (17.5)
High leisure time physical activity 27 (10.6) 8 (4.9) 122 (32.9) 81 (19.6)
Glu298Glu 112 (55.5) 110 (54.7) 195 (49.9) 212 (52.0)
Glu298Asp 75 (37.1) 78 (38.8) 157 (40.1) 165 (40.4)
Asp298Asp 15 (7.4) 13 (6.5) 39 (10.0) 31 (7.6)
Data are means and (SD), or numbers (n) and (%). Means were adjusted for age difference and proportions were standardised to the population in 
Skara. Genotype distributions were in HW. HDL, High-Density Lipoproteins;
LDL, Low-Density Lipoproteins; LTPA; leisure time physical activity.BMC Cardiovascular Disorders 2008, 8:36 http://www.biomedcentral.com/1471-2261/8/36
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between sex the eNOS genotype status (using a recessive
and dominant model alternatively) with respect to AMI
risk. All tests were two-sided and statistical significance
was assumed at p < 0.05.
Results
Baseline characteristics of the 1202 subjects that were suc-
cessfully genotyped and included are shown in table 1.
The overall genotype distribution was found to be in HW
equilibrium (table 1) and in the range of that previously
described in a southern Swedish population [24]. T2DM
(HR 4.04 [2.61–6.27], p < 0.001) was an independent risk
factor for AMI in a multivariate model (adjusted for age
and sex), and remained significant when also entering the
eNOS Asp298  dichotomized using a recessive model
(Asp298/Asp298  versus Asp298/Glu298+ Glu298/Glu298).
Male sex was a statistically significant risk factor for AMI
in the population reference group (2.73 [1.21–6.17], p =
0.016), however, not among subjects with T2DM (1.37
[0.89–2.10], p = 0.152).
In order to test the hypothesis that the genotype effect is
manifested in the subgroup of patients with T2DM, we
analysed the effect of the eNOS Asp298 allele using the sub-
jects with Glu298/Glu298 as reference group, stratifying for
diabetes, and adjusting for age, BMI, systolic blood pres-
sure, serum triglycerides, HDL -cholesterol, current smok-
ing, and leisure time physical activity. We found a
significant risk for AMI associated with the Asp298/Asp298
genotype compared to the wild type Glu298/Glu298 among
patients with T2DM (HR 3.12 CI [1.49–6.56], p = 0.003)
but no association between eNOS genotype and AMI in
subjects without T2DM (HR 0.45 [0.18–1.11], p = 0.083).
When stratifying for sex, we found a significant risk asso-
ciation in women with T2DM (OR 3.56 [1.16–10.90], p =
0.026) (table 2), which could not be fully confirmed in
men with T2DM (OR 2.67 [0.96–7.41], p = 0.059). No
significant risk associations between AMI and the Asp298/
Asp298 genotype can be found in subjects without diabetes
of either sex. An interaction term between sex and the
eNOS genotype dichotomized using the recessive model
for the genetic effect was non-significant both in subjects
with and without T2DM.
In order to test the hypothesis of synergism between
T2DM and the Asp298 allele in predisposing to AMI, we
stratified the study population by genotype (Glu298/
Glu298, Asp298/Glu298, Asp298/Asp298) and T2DM (DM +/-
), thereby generating six groups. We compared the six
groups using as reference group the subjects without dia-
betes and hypertension who were wild type homozygotes.
The synergistic pattern is illustrated in figure 1. Among
subjects without diabetes and hypertension, neither heter-
ozygotes nor homozygotes for the Asp298 allele had an
Table 2: Hazard ratios of a MI exploring a recessive effect of the Asp 298 polymorphism, with Glu298Glu as reference category, in men 
and women with T2DM.
No MI MI
Men n = 156 (%) n = 46 (%) HR 95%CI p
Patients with T2DM
Adjusted for differences in age:
Glu298Glu 89 79.5 23 20.5 1.00
Glu298Asp 57 76.0 18 24.0 1.13 0.61.2.09 0.705
Asp298Asp 10 66.7 5 33.3 2.54 0.95–6.79 0.064
Adjusted for differences in age, smoking, BMI, systolic blood pressure, HDL-cholesterol, serum triglycerides, and LTPA:
Glu298Glu 1.00
Glu298Asp 1.25 0.65–2.39 0.499
Asp298Asp 2.67 0.96–7.41 0.059
No MI MI
Women n = 162 (%) n = 39 (%) HR 95%CI p
Patients with T2DM
Adjusted for differences in age:
Glu298Glu 90 81.8 20 18.2 1.00
Glu298Asp 64 82.1 14 17.9 0.92 0.46–1.84 0.808
Asp298Asp 8 61.5 5 38.5 2.97 1.11–7.95 0.030
Adjusted for differences in age, smoking, BMI, systolic blood pressure, HDL-cholesterol, serum triglycerides, and LTPA:
Glu298Glu 1.00
Glu298Asp 1.11 0.52–2.36 0.790
Asp298Asp 3.56 1.16–10.90 0.026
Hazard ratios (HR) with 95% confidence intervals (955CI) were estimated using multivariate Cox proportional hazard models. BMI; body mass 
index. LTPA; leisure time physical activity.BMC Cardiovascular Disorders 2008, 8:36 http://www.biomedcentral.com/1471-2261/8/36
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increased risk for AMI compared to the reference group.
The three groups of patients with T2DM all had a signifi-
cantly increased risk for AMI compared to the reference
group, but in the homozygotes for the Asp298 allele, this
risk was markedly higher (OR 7.05 CI [2.96–16.82], p <
0.001). When stratifying for sex, this pattern seemed
stronger in women (OR 11.46 [2.63–49.97], p < 0.001)
than in men (OR 5.40 [1.77–16.52] p = 0.003) (all values
adjusted for differences in age, LTPA, smoking, BMI, systo-
lic blood pressure, HDL-cholesterol, and serum triglycer-
ides).
Discussion
Our findings show that T2DM is a significant independent
risk factor for AMI in both men and women, and that in a
subgroup of patients with T2DM, homozygosity for the
eNOS Asp298 allele is a significant risk factor for AMI. The
eNOS polymorphism has been investigated as a risk factor
for cardiovascular disease in numerous studies, and a
meta analysis including 23 028 patients showed that
homozygosity for the Asp298 allele is associated with a
moderately increased risk for IHD [10]. T2DM and insulin
resistance are characterized by increased prevalence of car-
diovascular disease, and although endothelial dysfunc-
tion has been linked to T2DM [25,26] few studies have
assessed a possible link between genetic variation in the
eNOS gene and the occurrence of T2DM disease. Conflict-
ing results have been reported [12,27-29], however in a
large prospective study that included over 24 000 subjects,
Conen et al [29] found no evidence for an association
between the occurrence of T2DM and any single genetic
polymorphism or haplotype in the eNOS gene locus.
Together with our data, this would suggest that the eNOS
pathway is not an important pathological bottleneck in
development of T2DM, but has a significant role in proc-
esses leading to AMI in patients with already established
T2DM.
The comparatively high HR:s we here find restricted to the
subgroup of patients with T2DM follow a pattern from
previous findings where significant HR:s were detectable
in defined subgroups carrying additional atherosclerosis
risk factors [30] but not in the overall materials. Together,
it supports a hypothesis of that when common factors are
combined, each with moderate effect on the NO pathway,
synergistic mechanisms could result in a significantly
increased risk.
In a previous study, a significant modulation of NO for-
mation in plasma due to genetic variations in eNOS gene
could not be found when individual polymorphisms
(including the Glu298Asp) were analysed, but was
detected when these polymorphisms were combined into
haplotypes in the analysis [31]. This suggests that a com-
bined effect of different genetic variants in the eNOS gene
also could exist, and it is possible that an extended haplo-
type analysis covering other polymorphisms in the eNOS
gene could have resulted in an even stronger association
between AMI and a specific eNOS haplotype in T2DM
subject than we show here for the Glu298Asp polymor-
phism.
The risk of myocardial infarction as compared to the refer- ence group of wild type non-diabetics (adjusted for age, sex,  smoking, BMI, systolic blood pressure, HDL-cholesterol,  serum triglycerides, and LTPA) in women (A) or men (B) Figure 1
The risk of myocardial infarction as compared to the 
reference group of wild type non-diabetics (adjusted 
for age, sex, smoking, BMI, systolic blood pressure, 
HDL-cholesterol, serum triglycerides, and LTPA) in 
women (A) or men (B). Homozyogosity for the eNOS 
Asp298 allele is a significant risk factor of greater magnitude in 
women than in men. * significant (p = 0.001). **significant (p 
= 0.003)
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It has previously been shown that pre-menopausal
women have a lower risk of developing cardiovascular dis-
ease than similarly aged men but that this female advan-
tage is reversed in persons with diabetes [17,32]. The
effect of T2DM on fatal AMI appears significantly stronger
in women than in men independent of other major cardi-
ovascular risk factors [17]. Our results indicate that the
eNOS pathway could be more important in women than
in men regarding the T2DM-associated MI risk, and may
offer part of an explanation for the higher risk increase
observed when women get T2DM, compared to men
[17,32]. The reason for a sex difference remains unclear
but known mechanisms based on hormonal differences
make plausible hypotheses.
Two factors that modulate the development of cardiovas-
cular diseases are HDL and estradiol [33,34], both which
also can promote the stimulation of eNOS and generation
of nitric oxide [35,36]. A large part of the protective effect
of HDL in cardiovascular disease is attributed to its role in
reverse cholesterol transport [34]. Interestingly, in both
mice and humans, female HDL but not male HDL has
been shown to stimulate eNOS [37]. This effect was
restricted to pre-menopausal HDL and shown to be due to
estradiol associated with the lipoprotein [37]. This inabil-
ity of postmenopausal HDL to stimulate eNOS [37] agrees
with a more severe endothelial dysfunction in women
after menopause and the increased cardiovascular disease
risk [38]. If eNOS stimulation rely on partly different
mechanisms in men and women under normal physio-
logical conditions, women after menopause would be
more susceptible/vulnerable to any additional factors that
impair eNOS function and NO bioavailability than men,
and this could offer a putative explanation to why the
combined effect of T2DM and the Asp298 allele is stronger
in women than in men in our survey. The majority of
women in our study were older than 50 years at baseline,
and can reasonably be presumed to be past menopause,
however definite data on menopause status was not avail-
able. HDL from postmenopausal women receiving estro-
gen replacement therapy has been shown to stimulate
eNOS [37] and initial epidemiological studies indicated a
protective effect against coronary artery disease [39].
However, two large controlled studies have shown that
postmenopausal hormone therapy actually can increase
the risk of cardiovascular disease [40,41]. Although exact
data is not available in our study regarding the use of hor-
mone replacement therapy (HRT), it was generally low in
this population during the time of the study, and HRT use
is therefore not likely to influence our results.
The study has some limitations. We have not followed the
health status of the control population regarding diabetic
status after baseline surveillance/inclusion. However, this
misclassification may rather underestimate the risk here
observed, since patients with T2DM may exist in the pop-
ulation control material. Stratification into T2DM, geno-
type and sex results in small numbers within groups.
However, we still find significant associations and a con-
sistent pattern when exploring biologically plausible
mechanisms supported by previously published in vitro
and in vivo data. A strength of this study is the availability
of data that make it possible to adjust for several impor-
tant confounding risk factors. However, although we
adjust for major possible confounders such as age, LTPA,
smoking, BMI, systolic blood pressure, HDL-cholesterol,
and serum triglycerides, others may still not be accounted
for. Previous results have indicated that effects of statins
can be modulated by eNOS polymorphism, but unfortu-
nately we have no information on the use of statins at
baseline. However, these surveys were conducted 1992–
1994, and the use of statins was generally low in Swedish
primary care at that time. We choose not to include indi-
viduals with hypertension in the reference group to allow
for testing specifically the role of the eNOS polymorphism
in predisposing to acute myocardial infarction in type 2
diabetics. Moreover, to include subjects with hyperten-
sion into the population reference group would have
introduced a misclassification, as more than 50% of sub-
jects with hypertension also have diabetes. More strengths
of the study are that the study population is of a reasona-
bly large size and with a high participation rate, and fur-
thermore that it is a population-based study where
patients are consecutively recruited in primary care and
not through specialist clinics, and that the reference sub-
jects come from the population in the same community.
Together, this makes it probable that our findings reflect a
risk association that is general to patients with T2DM.
Conclusion
We show a strong independent association of the eNOS
genotype with myocardial infarction in patients with
T2DM and which is emphasized in females. This supports
the role of eNOS as an important pathological bottleneck
in cardiovascular disease and a possible target of interven-
tion. Secondary prevention that involves factors which
influence eNOS function and NO bioavailability may be
of even more benefit among patients with T2DM, espe-
cially in women. The observed sex difference also suggest
that more aggressive or pre-emptive pharmacological
treatment with commonly used drugs that promote eNOS
activity or NO bioavailability (statins, angiotensinogen
inhibitors, AT-1 blockers, folate, antioxidants) [2,8,42]
could be considered in women with T2DM. Whether there
is a potential beneficial and sex-dependent effect of treat-
ment with direct or indirect NO donors for preventing car-
diovascular disease in patients with T2DM could be of
interest to explore further [7,8].BMC Cardiovascular Disorders 2008, 8:36 http://www.biomedcentral.com/1471-2261/8/36
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